Public trial registry of the CCC-Munich

Trial CLL13

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
CLL13
World
Full title
:

A phase 3 multicenter, randomized, prospective, open-label trial of standard chemoimmunotherapy (FCR/BR) versus rituximab plus venetoclax (RVe) versus obinutuzumab (GA101) plus venetoclax (GVe) versus obinutuzumab plus ibrutinib plus venetoclax (GIVe) in fit patients with previously untreated chronic lymphocytic leukemia (CLL) without del(17p) or TP53 mutation

World
NCT number
:
World
Responsible organization
:
3. Med 3. Med Ismaninger Str. 22 81675 München Germany Tum
Indications
Classification Code Description
- C91.1 Chronische lymphatische Leukämie vom B-Zell-Typ [CLL]
Trial design
World
Phase
:
III
Status
World
Status
:
Recruitment active
Votes
Initiiation & lock
World
Date of lock (planned / actual)
:
Unknown / Unknown
Therapy
World
Therapy
:

Chemo

Participants
Function Prename Surname Organization
World Responsible contact Christian Bogner Keine Organisationseinheit angegeben Magnifier